Accepted Manuscript

Mitochondrial disorders of the retinal ganglion cells and the optic nerve



Josef Finsterer, Michelangelo Mancuso, Davide Pareyson, Jean-Marc Burgunder, Thomas Klopstock

PII:	S1567-7249(17)30022-3
DOI:	doi:10.1016/j.mito.2017.10.003
Reference:	MITOCH 1229
To appear in:	Mitochondrion
Received date:	24 January 2017
Revised date:	2 October 2017
Accepted date:	6 October 2017

Please cite this article as: Josef Finsterer, Michelangelo Mancuso, Davide Pareyson, Jean-Marc Burgunder, Thomas Klopstock, Mitochondrial disorders of the retinal ganglion cells and the optic nerve. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Mitoch(2017), doi:10.1016/j.mito.2017.10.003

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Mitochondrial disorders of the retinal ganglion cells and the optic nerve

Josef Finsterer, MD, PhD [1], Michelangelo Mancuso, MD [2], Davide Pareyson, MD [3] Jean-Marc Burgunder, MD [4], Thomas Klopstock, MD [5]

[1] Krankenanstalt Rudolfstiftung, Vienna, Austria, fifigs1@yahoo.de

[2] Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Italy, mancusomichelangelo@gmail.com

[3] Department of Clinical Neurosciences, C. Besta Neurological Institute, IRCCS Foundation, Milan, Italy, davide.pareyson@istituto-besta.it

[4] Departments of Neurology, University of Bern (Switzerland), Sun Yat Sen University, Guangzhou (China) and Sichuan University, Chendgu (China), jmburgunder@bluewin.ch

[5] Department of Neurology, Friedrich-Baur Institute, Ludwig-Maximilians-Universität München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. Thomas.Klopstock@med.LMU.de

Number of authors: 5 Number of words, abstract: 234 Number of words, body: 4721 Number of references: 165 Number of tables: 3 Number of figures: 0

Contribution of authors

JF designed the review, organized the literature, and wrote the first draft of the manuscript. TK, MM, DP; and J-MB completed the literature search, supported in the writing, provided critical comments, gave feedback, and helped to finalise the manuscript.

Disclaimers (Conflicts of interest)

JF, MM, DP, and J-MB: nothing to declare

TK has been a principal investigator or investigator on industry-sponsored trials funded by Santhera Pharmaceuticals Ltd (idebenone in LHON, idebenone in Friedreich ataxia), GenSight Biologics (gene therapy in LHON) and by H. Lundbeck A/S (carbamylated erythropoietin in Friedreich ataxia). He has received research support from government entities (German Research Foundation; German Federal Ministry of Education and Research; European Commission 7th Framework Programme) and from commercial entities (Santhera Pharmaceuticals Ltd; Actelion Pharmaceuticals Ltd; H. Lundbeck A/S; GenSight Biologics). He has been serving on scientific advisory boards for commercial entities (Santhera Pharmaceuticals Ltd; Actelion Pharmaceuticals Ltd) and for non-profit Download English Version:

https://daneshyari.com/en/article/8962078

Download Persian Version:

https://daneshyari.com/article/8962078

Daneshyari.com